WCLC 2024 - Longitudinal Tumor Microenvironment Analysis in Extensive Stage SCLC Patients Treated with Dual Checkpoint Inhibitor Blockade

WCLC 2024 - Longitudinal Tumor Microenvironment Analysis in Extensive Stage SCLC Patients Treated with Dual Checkpoint Inhibitor Blockade

WCLC 2024 - Longitudinal Tumor Microenvironment Analysis in Extensive Stage SCLC Patients Treated with Dual Checkpoint Inhibitor Blockade

WCLC 2024 - Longitudinal Tumor Microenvironment Analysis in Extensive Stage SCLC Patients Treated with Dual Checkpoint Inhibitor Blockade

Significant increase in both CD8+ effector T cells and CD4+ helper T cells observed at week 4 compared to baseline samples without significant change in FoxP3+ regulatory T cells

CD4+ helper T cells exhibited the greatest expansion in patients with clinical activity (CA), i.e. PR/SD, whereas FoxP3+ regulatory T cells were increased among those with no clinical activity (NCA), i.e. PD.

Tumors at progression showed a notable reduction of TILs, comparable to baseline levels.
Significant increase in both CD8+ effector T cells and CD4+ helper T cells observed at week 4 compared to baseline samples without significant change in FoxP3+ regulatory T cells

CD4+ helper T cells exhibited the greatest expansion in patients with clinical activity (CA), i.e. PR/SD, whereas FoxP3+ regulatory T cells were increased among those with no clinical activity (NCA), i.e. PD.

Tumors at progression showed a notable reduction of TILs, comparable to baseline levels.
Significant increase in both CD8+ effector T cells and CD4+ helper T cells observed at week 4 compared to baseline samples without significant change in FoxP3+ regulatory T cells

CD4+ helper T cells exhibited the greatest expansion in patients with clinical activity (CA), i.e. PR/SD, whereas FoxP3+ regulatory T cells were increased among those with no clinical activity (NCA), i.e. PD.

Tumors at progression showed a notable reduction of TILs, comparable to baseline levels.
Significant increase in both CD8+ effector T cells and CD4+ helper T cells observed at week 4 compared to baseline samples without significant change in FoxP3+ regulatory T cells

CD4+ helper T cells exhibited the greatest expansion in patients with clinical activity (CA), i.e. PR/SD, whereas FoxP3+ regulatory T cells were increased among those with no clinical activity (NCA), i.e. PD.

Tumors at progression showed a notable reduction of TILs, comparable to baseline levels.